These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 21475129)

  • 21. A parallel dose-escalation study of weekly and twice-weekly bortezomib in combination with gemcitabine and cisplatin in the first-line treatment of patients with advanced solid tumors.
    Voortman J; Smit EF; Honeywell R; Kuenen BC; Peters GJ; van de Velde H; Giaccone G
    Clin Cancer Res; 2007 Jun; 13(12):3642-51. PubMed ID: 17575229
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A dose-escalation study of irinotecan (CPT-11) in combination with gemcitabine in patients with advanced non-small cell lung cancer previously treated with a cisplatin-based front line chemotherapy.
    Kakolyris SS; Kouroussis C; Koukourakis M; Kalbakis K; Mavroudis D; Vardakis N; Georgoulias V
    Anticancer Res; 2002; 22(3):1891-6. PubMed ID: 12168889
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A phase I trial of gemcitabine plus cladribine in patients with advanced hematologic malignant diseases.
    Odenike OM; Sobecks RM; Janisch L; Huo D; Zimmerman TM; Daugherty CK; Ratain MJ; Larson RA
    Cancer Chemother Pharmacol; 2004 Dec; 54(6):553-61. PubMed ID: 15349753
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment of resistant metastatic melanoma using sequential epigenetic therapy (decitabine and panobinostat) combined with chemotherapy (temozolomide).
    Xia C; Leon-Ferre R; Laux D; Deutsch J; Smith BJ; Frees M; Milhem M
    Cancer Chemother Pharmacol; 2014 Oct; 74(4):691-7. PubMed ID: 25062770
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A phase I trial of BMS-247550 (NSC# 710428) and gemcitabine in patients with advanced solid tumors.
    Hensley ML; Dizon D; Derosa F; Venkatraman E; Sabbatini P; Chi DS; Dupont J; Colevas AD; Spriggs D; Aghajanian C
    Invest New Drugs; 2007 Aug; 25(4):335-41. PubMed ID: 17364235
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A dose escalation study of docetaxel plus capecitabine in combination with gemcitabine in patients with advanced solid tumors.
    Amarantidis K; Houhouli K; Papatheodorou K; Miloussis A; Matthaios D; Chatzaki E; Lyrantzopoulos N; Tsaroucha A; Tentes A; Kakolyris S
    Oncol Res; 2006; 16(6):281-7. PubMed ID: 17476973
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase I dose-escalating study of panobinostat (LBH589) administered intravenously to Japanese patients with advanced solid tumors.
    Morita S; Oizumi S; Minami H; Kitagawa K; Komatsu Y; Fujiwara Y; Inada M; Yuki S; Kiyota N; Mitsuma A; Sawaki M; Tanii H; Kimura J; Ando Y
    Invest New Drugs; 2012 Oct; 30(5):1950-7. PubMed ID: 21964801
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A phase 1b study of trametinib, an oral Mitogen-activated protein kinase kinase (MEK) inhibitor, in combination with gemcitabine in advanced solid tumours.
    Infante JR; Papadopoulos KP; Bendell JC; Patnaik A; Burris HA; Rasco D; Jones SF; Smith L; Cox DS; Durante M; Bellew KM; Park JJ; Le NT; Tolcher AW
    Eur J Cancer; 2013 Jun; 49(9):2077-85. PubMed ID: 23583440
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase I trial of gemcitabine and CPT-11 given weekly for four weeks every six weeks.
    Alberts SR; Erlichman C; Sloan J; Okuno SH; Burch PA; Rubin J; Pitot HC; Goldberg RM; Adjei AA; Atherton PJ; Kaufmann SH
    Ann Oncol; 2001 May; 12(5):627-31. PubMed ID: 11432620
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase I clinical study of infusional 5-fluorouracil with oxaliplatin and gemcitabine (FOG regimen) in patients with solid tumors.
    Goel S; Bulgaru A; Hochster H; Wadler S; Zamboni W; Egorin M; Ivy P; Leibes L; Muggia F; Lockwood G; Harvey E; Renshaw G; Mani S
    Ann Oncol; 2003 Nov; 14(11):1682-7. PubMed ID: 14581279
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase I trial of gemcitabine, doxorubicin and cisplatin (GAP) in patients with advanced solid tumors.
    Duran I; Siu LL; Chen EX; Oza AM; Sturgeon J; Chin SF; Brown S; Pond GR; Nottage M
    Anticancer Drugs; 2006 Jan; 17(1):81-7. PubMed ID: 16317294
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phase I-II study of gemcitabine and fluorouracil as a continuous infusion in patients with pancreatic cancer.
    Hidalgo M; Castellano D; Paz-Ares L; Gravalos C; Diaz-Puente M; Hitt R; Alonso S; Cortes-Funes H
    J Clin Oncol; 1999 Feb; 17(2):585-92. PubMed ID: 10080603
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dose finding and early efficacy study of gemcitabine plus capecitabine in combination with bevacizumab plus erlotinib in advanced pancreatic cancer.
    Starling N; Watkins D; Cunningham D; Thomas J; Webb J; Brown G; Thomas K; Oates J; Chau I
    J Clin Oncol; 2009 Nov; 27(33):5499-505. PubMed ID: 19858399
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A phase I study of prolonged infusion of triapine in combination with fixed dose rate gemcitabine in patients with advanced solid tumors.
    Mortazavi A; Ling Y; Martin LK; Wei L; Phelps MA; Liu Z; Harper EJ; Ivy SP; Wu X; Zhou BS; Liu X; Deam D; Monk JP; Hicks WJ; Yen Y; Otterson GA; Grever MR; Bekaii-Saab T
    Invest New Drugs; 2013 Jun; 31(3):685-95. PubMed ID: 22847785
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dose escalation study on oxaliplatin and capecitabine (Xeloda) in patients with advanced solid tumors.
    Kakolyris S; Souglakos J; Kouroussis C; Androulakis N; Samonis G; Vardakis N; Amarantidis K; Agelaki S; Mavroudis D; Xenidis N; Georgoulias V
    Oncology; 2004; 66(4):253-9. PubMed ID: 15218291
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase I study of bryostatin 1 and gemcitabine.
    El-Rayes BF; Gadgeel S; Shields AF; Manza S; Lorusso P; Philip PA
    Clin Cancer Res; 2006 Dec; 12(23):7059-62. PubMed ID: 17145828
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase I/IIa study of cetuximab with gemcitabine plus carboplatin in patients with chemotherapy-naive advanced non-small-cell lung cancer.
    Robert F; Blumenschein G; Herbst RS; Fossella FV; Tseng J; Saleh MN; Needle M
    J Clin Oncol; 2005 Dec; 23(36):9089-96. PubMed ID: 16301597
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phase I study of docetaxel dose escalation in combination with fixed weekly gemcitabine in patients with advanced malignancies.
    Spiridonidis CH; Laufman LR; Jones J; Rhodes VA; Wallace K; Nicol S
    J Clin Oncol; 1998 Dec; 16(12):3866-73. PubMed ID: 9850032
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A phase I clinical trial of navitoclax, a targeted high-affinity Bcl-2 family inhibitor, in combination with gemcitabine in patients with solid tumors.
    Cleary JM; Lima CM; Hurwitz HI; Montero AJ; Franklin C; Yang J; Graham A; Busman T; Mabry M; Holen K; Shapiro GI; Uronis H
    Invest New Drugs; 2014 Oct; 32(5):937-45. PubMed ID: 24916770
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase I trial of vandetanib in combination with gemcitabine and capecitabine in patients with advanced solid tumors with an expanded cohort in pancreatic and biliary cancers.
    Kessler ER; Eckhardt SG; Pitts TM; Bradshaw-Pierce EL; O'byrant CL; Messersmith WA; Nallapreddy S; Weekes C; Spratlin J; Lieu CH; Kane MA; Eppers S; Freas E; Leong S
    Invest New Drugs; 2016 Apr; 34(2):176-83. PubMed ID: 26715573
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.